DSMB hits pause on Voyager's Neurocrine-partnered Parkinson's gene therapy
Voyager Therapeutics’ clinical plans have hit another snag.
The Cambridge biotech disclosed in their third quarter earnings Monday that the data safety and monitoring board has recommended halting enrollment on their pivotal Phase II trial testing their lead gene therapy for Parkinson’s disease. Voyager and their partner Neurocrine had already paused enrollment because of Covid-19, but will now postpone plans to resume the study.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 109,800+ biopharma pros reading Endpoints daily — and it's free.